Core Viewpoint - Kingmed Diagnostics has experienced a continuous decline in stock price, with a total drop of 7.11% over the past six days, indicating potential concerns among investors regarding the company's performance and market conditions [1]. Company Overview - Kingmed Diagnostics, established on May 26, 2006, and listed on September 8, 2017, is located in Guangzhou, Guangdong Province. The company provides a wide range of diagnostic services to over 23,000 medical institutions across China, offering nearly 80 types of testing technologies and approximately 3,200 testing projects [1]. - The main revenue composition of Kingmed Diagnostics includes: 91.20% from medical diagnostic services, 6.45% from sales of diagnostics, 1.47% from other services, 0.62% from cold chain logistics, and 0.27% from health check-up services [1]. Shareholder Insights - Among the top shareholders of Kingmed Diagnostics, Huabao Fund's Huabao CSI Medical ETF (512170) reduced its holdings by 84,000 shares in the second quarter, now holding 9.13 million shares, which accounts for 1.98% of the circulating shares. The estimated floating loss today is approximately 3.74 million yuan, with a total floating loss of 21.18 million yuan during the six-day decline [2]. - The Huabao CSI Medical ETF was established on May 20, 2019, with a current scale of 26.15 billion yuan. Year-to-date returns are 18.89%, ranking 2640 out of 4222 in its category, while the one-year return is 42.38%, ranking 2435 out of 3813 [2].

Core Viewpoint - The company will hold an online performance briefing on September 19, 2025, to discuss its half-year results and address investor questions [2][3][4]. Group 1: Meeting Details - The performance briefing is scheduled for September 19, 2025, from 15:30 to 17:00 [4]. - The meeting will take place on the "Panorama Roadshow" website [4]. - The format of the meeting will be an interactive text-based online session [3][5]. Group 2: Participation Information - Investors can participate in the interactive session on the "Panorama Roadshow" website during the specified time [5]. - Questions can be submitted via email to the company's securities affairs department by September 18, 2025, at 12:00 [5][6]. - The company will provide unified responses to commonly asked questions during the performance briefing [2][5]. Group 3: Contact Information - The contact department for inquiries is the Securities Affairs Department [6]. - The contact phone number is 020-29196326 [6]. - The email for question submissions is sid@kingmed.com.cn [7].

证券代码：603882 证券简称：金域医学 公告编号：2025-040 本次业绩说明会以网络文字互动方式召开，公司将针对 2025 年半年度经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 1 会议召开时间：2025 年 9 月 19 日（星期五）15:30-17:00 会议召开地点："全景路演"网站（http://rs.p5w.net） 会议召开方式：网络文字互动 广州金域医学检验集团股份有限公司 关于参加 2025 年广东辖区上市公司投资者网上集体 接待日暨召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 问题征集方式：投资者可于 2025 年 9 月 18 日中午 12:00 前将相关问题 通过电子邮件的形式发送至公司证券事务部邮箱：sid@kingmed.com.cn。本 公司将在业绩说明会上对投资者普遍关注的问题进行统一回答。 广州金域医学检验集团股份有限公司（以下简称"公司"）已于 2025 年 ...

Group 1 - The "Data Element ×" competition in Guangdong focuses on the innovative application of data in financial services and healthcare, with 63 projects competing in the finals [1][2] - The healthcare track featured 33 teams presenting solutions to address issues such as the uneven distribution of quality medical resources, enhancing service convenience, health monitoring, and personalized treatment [1][3] - The competition aims to explore the integration of data and healthcare, promoting digital transformation and high-quality development in the industry [1][6] Group 2 - The Guangdong Provincial Government and various health committees are guiding and hosting the competition, emphasizing the importance of data application in healthcare [2][5] - Notable projects include a comprehensive data platform for elderly care by Guangdong Provincial People's Hospital and a chest pain treatment system by Guangzhou Development Zone Hospital, showcasing innovative data-driven solutions [3][4] - The competition reflects Guangzhou's strong foundation in healthcare and data innovation, with plans to develop a 300 billion industry cluster in biomedicine and health over the next five years [7][8] Group 3 - The event is designed not only as a competition but also as a sustainable ecosystem for long-term development in the healthcare sector [8] - The Science City Digital Technology Group is facilitating the competition, aiming to enhance the value of data in healthcare through expert guidance and investment in AI infrastructure [8] - Guangzhou's market reforms in data elements are seen as a model for reducing compliance costs and stimulating innovation in the healthcare industry [7][8]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][41]. Core Views - The pharmaceutical sector has shown resilience, outperforming the overall market with a 1.40% increase, while the total A-share market declined by 1.17% [1][32]. - ANGPTL3 has gained significant interest from multinational pharmaceutical companies (MNCs) due to its unique mechanism of action, which is non-LDLR dependent, making it effective in patients with LDLR deficiencies [3][30]. - The report highlights the diverse drug forms targeting ANGPTL3, with MNCs like Novartis, Lilly, Amgen, and AstraZeneca actively investing in this area, indicating a potential for multi-target and multi-drug combinations in the future [3][16]. Summary by Sections Market Performance - The overall A-share market fell by 1.17%, with the Shanghai and Shenzhen 300 index down by 0.81%. The biotechnology sector, however, rose by 1.40%, indicating strong performance relative to the broader market [1][32]. - Specific segments within the pharmaceutical sector showed varied performance, with chemical pharmaceuticals up by 3.92% and medical services up by 1.69%, while medical devices and traditional Chinese medicine saw declines [1][32]. ANGPTL3 Developments - A collaboration between Argo Biopharma and Novartis was announced, focusing on RNA drugs for cardiovascular diseases, with a total potential payment of $5.2 billion, including a $160 million upfront payment [2][11]. - ANGPTL3's mechanism allows for significant reductions in LDL-C levels in patients with HoFH, outperforming traditional treatments like PCSK9 inhibitors [3][31]. Company Earnings Forecasts and Ratings - Key companies in the sector, such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital, have been rated as "Outperform" with projected net profits for 2024 ranging from 1.4 billion to 116.7 billion yuan [4][41]. - The report provides detailed earnings forecasts for various companies, indicating a positive outlook for the sector as a whole [4][41]. Valuation Metrics - The TTM price-to-earnings ratio for the pharmaceutical and biotechnology sector stands at 40.75x, significantly higher than the overall A-share market's 19.80x [37][38]. - Sub-sectors such as chemical pharmaceuticals and biological products have even higher valuations, indicating strong investor interest and growth potential [37][38]. Recommended Stocks - The report recommends several companies, including Mindray Medical for its strong market position and international expansion, WuXi AppTec for its comprehensive drug development services, and Aier Eye Hospital for its leading position in the eye care sector [41][42].

Group 1 - The core viewpoint of the announcement is the successful convening of the second extraordinary general meeting of shareholders in 2025, where all proposed resolutions were approved without any objections [2][4]. - The meeting was held on September 9, 2025, at the company's headquarters in Guangzhou, with all board members and supervisors present [2][3]. - The resolutions included the cancellation of the supervisory board and amendments to the company's articles of association and related rules, all of which were passed [3][4]. Group 2 - The meeting's voting procedures complied with the Company Law and the company's articles of association, ensuring the legitimacy of the proceedings [2][4]. - A total of nine directors and three supervisors attended the meeting, along with the company secretary and all senior executives [3][4]. - The legal firm Beijing Zhonglun Law Firm provided witness services, confirming that the meeting's procedures and voting results were valid and in accordance with relevant laws and regulations [4].

Group 1 - The core point of the article is that Kingmed Diagnostics announced the holding of its second extraordinary general meeting of shareholders in 2025 on September 9, 2025, where several proposals, including the amendment proposal, were approved [2]

证券代码：603882 证券简称：金域医学 公告编号：2025-039 广州金域医学检验集团股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2025 年 9 月 9 日 (二)股东会召开的地点：广州市国际生物岛螺旋三路 10 号金域医学总部大楼 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 611 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 221,099,623 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 47.7270 | (五)公司董事、监事和董事会秘书的出席情况 1、公司在任董事9人，出席9人； 2、公司在任监事 3 人，出席 3 人； 3、董事会秘书汪令来先生出席本次会议；公司全体高管列席本次会议。 二、议案审议情况 (四)表决方式 ...

北京市中伦律师事务所 关于广州金域医学检验集团股份有限公司 2025 年第二次临时股东会的 法律意见书 北京市朝阳区金和东路 20 号院正大中心 3 号南塔 22-31 层 邮编：100020 22-31/F, South Tower of CP Center, 20 Jin He East Avenue, Chaoyang District, Beijing l00020, P.R. China 电话/Tel : +86 10 5957 2288 传真/Fax : +86 10 6568 1022/1838 www.zhonglun.com 北京市中伦律师事务所 关于广州金域医学检验集团股份有限公司 2025 年第二次临时股东会的 二〇二五年九月 法律意见书 致：广州金域医学检验集团股份有限公司 北京市中伦律师事务所（以下简称"本所"）作为广州金域医学检验集团股 份有限公司（以下简称"公司"）的常年法律顾问，受公司委托，指派律师出席 公司 2025 年第二次临时股东会（以下简称"本次股东会"）。本所律师根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》 ...

Market Overview - The medical services sector increased by 2.28% on September 8, with King Med leading the gains [1] - The Shanghai Composite Index closed at 3826.84, up 0.38%, while the Shenzhen Component Index closed at 12666.84, up 0.61% [1] Top Performers - King Med (603882) closed at 33.31, up 7.94% with a trading volume of 301,000 shares and a transaction value of 99.866 million [1] - Yao Kang Bio (688046) closed at 18.75, up 6.29% with a trading volume of 74,800 shares and a transaction value of 138 million [1] - Digital Human (835670) closed at 19.24, up 5.54% with a trading volume of 101,700 shares and a transaction value of 192 million [1] Underperformers - Hai Te Bio (300683) closed at 41.67, down 2.53% with a trading volume of 86,900 shares and a transaction value of 361 million [2] - Chengda Pharmaceutical (301201) closed at 28.09, down 2.26% with a trading volume of 43,900 shares and a transaction value of 12.2 million [2] - Yi Nuo Si (688710) closed at 39.26, down 1.90% with a trading volume of 13,500 shares and a transaction value of 53.1306 million [2] Capital Flow - The medical services sector saw a net inflow of 115 million from institutional investors, while retail investors experienced a net outflow of 249 million [2][3] - Major stocks like King Med and Wu Yi Kang (603259) attracted significant institutional investment, with net inflows of 91.836 million and 79.3798 million respectively [3]